News articles about BioTelemetry (NASDAQ:BEAT) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. BioTelemetry earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.3946194080651 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Zacks: Brokerages Anticipate BioTelemetry Inc (BEAT) Will Announce Quarterly Sales of $91.63 Million (americanbankingnews.com)
- Globeflex Capital LP Stake in Biotelemetry INC (BEAT) Decreased (thecasualsmart.com)
- $0.25 EPS Expected for BioTelemetry, Inc. (BEAT); Cott (COT) Had 7 Bullish Analysts (mtastar.com)
- Diagnostic Electrocardiograph (ECG) Market Top Manufacturers by 2023: BioTelemetry, Suzuken, Philips and Fukuda … (newspharmaceuticals.com)
- Competing public offers in Switzerland – recent case law (lexology.com)
Shares of BEAT opened at $34.50 on Friday. The company has a market capitalization of $1,109.42, a P/E ratio of 35.57, a P/E/G ratio of 1.67 and a beta of 0.86. The company has a current ratio of 1.77, a quick ratio of 1.66 and a debt-to-equity ratio of 0.80. BioTelemetry has a 1-year low of $23.30 and a 1-year high of $39.20.
A number of equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of BioTelemetry from a “buy” rating to a “hold” rating in a report on Wednesday, March 21st. TheStreet downgraded shares of BioTelemetry from a “b-” rating to a “c” rating in a report on Tuesday, March 20th. Zacks Investment Research downgraded shares of BioTelemetry from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Finally, Dougherty & Co reaffirmed a “buy” rating and issued a $41.00 target price (up from $40.00) on shares of BioTelemetry in a research note on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $43.00.
In related news, insider Fred Broadway sold 54,158 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $34.17, for a total value of $1,850,578.86. Following the sale, the insider now directly owns 64,880 shares of the company’s stock, valued at $2,216,949.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 9.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2018/04/21/biotelemetry-beat-earning-somewhat-positive-press-coverage-study-finds.html.
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.